Literature DB >> 19761432

Role of nucleophosmin in acute myeloid leukemia.

Natalia Meani1, Myriam Alcalay.   

Abstract

Nucleophosmin (NPM) is a nucleolar phosphoprotein implicated in the regulation of multiple cellular functions, which possesses both oncogenic and tumor-suppressor properties. Mutations of the NPM1 gene leading to the expression of a cytoplasmic mutant protein, NPMc+, are the most frequent genetic abnormalities found in acute myeloid leukemias. Acute myeloid leukemias with mutated NPM1 have distinct characteristics, including a significant association with a normal karyotype, involvement of different hematopoietic lineages, a specific gene-expression profile and clinically, a better response to induction therapy and a favorable prognosis. NPMc+ maintains the capacity of wild-type NPM to interact with a variety of cellular proteins, and impairs their activity by delocalizing them to the cytoplasm. In this review we summarize recent discoveries concerning NPM function, and discuss their possible impact on the pathogenesis of acute myeloid leukemias with mutated NPM1.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19761432     DOI: 10.1586/era.09.84

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN: 1473-7140            Impact factor:   4.512


  14 in total

Review 1.  Expression, function, and targeting of the nuclear exporter chromosome region maintenance 1 (CRM1) protein.

Authors:  Jo Ishizawa; Kensuke Kojima; Numsen Hail; Yoko Tabe; Michael Andreeff
Journal:  Pharmacol Ther       Date:  2015-06-03       Impact factor: 12.310

2.  Cytoplasmic FANCA-FANCC complex interacts and stabilizes the cytoplasm-dislocalized leukemic nucleophosmin protein (NPMc).

Authors:  Wei Du; Jie Li; Jared Sipple; Jianjun Chen; Qishen Pang
Journal:  J Biol Chem       Date:  2010-09-23       Impact factor: 5.157

3.  Differential response to cytotoxic therapy explains treatment dynamics of acute myeloid leukaemia patients: insights from a mathematical modelling approach.

Authors:  H Hoffmann; C Thiede; I Glauche; M Bornhaeuser; I Roeder
Journal:  J R Soc Interface       Date:  2020-09-09       Impact factor: 4.118

4.  Nucleophosmin deposition during mRNA 3' end processing influences poly(A) tail length.

Authors:  Fumihiko Sagawa; Hend Ibrahim; Angela L Morrison; Carol J Wilusz; Jeffrey Wilusz
Journal:  EMBO J       Date:  2011-08-05       Impact factor: 11.598

5.  A multiprotein binding interface in an intrinsically disordered region of the tumor suppressor protein interferon regulatory factor-1.

Authors:  Vikram Narayan; Petr Halada; Lenka Hernychová; Yuh Ping Chong; Jitka Žáková; Ted R Hupp; Borivoj Vojtesek; Kathryn L Ball
Journal:  J Biol Chem       Date:  2011-01-18       Impact factor: 5.157

6.  Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia.

Authors:  Parvathi Ranganathan; Xueyan Yu; Caroline Na; Ramasamy Santhanam; Sharon Shacham; Michael Kauffman; Alison Walker; Rebecca Klisovic; William Blum; Michael Caligiuri; Carlo M Croce; Guido Marcucci; Ramiro Garzon
Journal:  Blood       Date:  2012-06-07       Impact factor: 22.113

7.  Nucleophosmin, a critical Bax cofactor in ischemia-induced cell death.

Authors:  Zhiyong Wang; Jonathan M Gall; Ramon Bonegio; Andrea Havasi; Katarina Illanes; John H Schwartz; Steven C Borkan
Journal:  Mol Cell Biol       Date:  2013-03-04       Impact factor: 4.272

Review 8.  Dysregulation of RNA polymerase I transcription during disease.

Authors:  K M Hannan; E Sanij; L I Rothblum; R D Hannan; R B Pearson
Journal:  Biochim Biophys Acta       Date:  2012-11-12

Review 9.  Molecular-based classification of acute myeloid leukemia and its role in directing rational therapy: personalized medicine for profoundly promiscuous proliferations.

Authors:  Gerald B W Wertheim; Elizabeth Hexner; Adam Bagg
Journal:  Mol Diagn Ther       Date:  2012-12       Impact factor: 4.074

10.  Humoral autoimmune response to nucleophosmin in the immunodiagnosis of hepatocellular carcinoma.

Authors:  Mei Liu; Armando Varela-Ramirez; Jitian Li; Liping Dai; Renato J Aguilera; Jian-Ying Zhang
Journal:  Oncol Rep       Date:  2015-03-16       Impact factor: 3.906

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.